C2N Diagnostics

09/03/2025

C2N Diagnostics is proud to announce that its early achievements while based in St. Louis are allowing it to triple the size of its operations in its hometown.

C2N expresses its thanks to the following for their support throughout the process: Governor Mike Kehoe; Mayor Cara Spencer, City of St. Louis; Alderman Michael Browning, City of St. Louis; Cortex Innovation Community; Cushman & Wakefield; Greater St. Louis, Inc.; Missouri Department of Economic Development; St. Louis Development Corporation; and Washington University in St. Louis.



https://c2n.com/news-releases/dynamic-growth-leads-c2n-diagnostics-to-expand-st-louis-headquarters-to-meet-global-need-for-answers-to-alzheimers-disease-nbsp

08/25/2025

Clinicians worried about early-onset Alzheimer’s disease in patients with cognitive concerns between the ages of 50 and 55 years can now prescribe the PrecivityAD2™ blood test to aid in the diagnosis of the neurological disorder for that expanded population.

The test helps healthcare professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and helps inform medical management and treatment decisions.

Please see here for more details on this important news! https://precivityad.com/news/c2n-diagnostics-expands-the-precivityad2-alzheimers-disease-blood-test-intended-use-to-patients-50-years-and-older

Lower Age Limit Addresses Increasing Calls from Clinicians Seeking Access to the PrecivityAD2™ Test for Patients With Earlier Onset of Cognitive Symptoms; Test Provides Potential to Inform Earlier Intervention   ST. LOUIS — Aug. 25, 2025 — Clinicians worried about early-onset Alzheimer

08/07/2025

C2N Diagnostics is proud to be a sponsor of the Alzheimer Europe Anti-Stigma Award, which recognizes an outstanding initiative aimed at combating stigma and promoting a positive image of dementia and people living with dementia.

It’s open to artists who are using photography or painting to address stigma and convey a positive image of dementia and people living with dementia.

The deadline is soon: Sept. 1
https://bit.ly/AEAntiStigmaAward

See last year’s top awardee at https://www.alzheimer-europe.org/our-work/anti-stigma-award/anti-stigma-initiatives/documentary-film-alzheimer-mit-56-das?language_content_entity=en

Photo is of winners of the Anti-Stigma Award 2024 (left to right): Magnus Renggli, Ofelya Kamavosyan, Andreas Kreimaier

08/04/2025

C2N Diagnostics is always proud to acknowledge generous support from the Alzheimer's Drug Discovery Foundation.

Pharmaceutical Executive interviewed ADDF’s Chief Financial Officer Karen B. Harris and she provided further insights into how ADDF views C2N and its PrecivityAD™ line of blood tests that help healthcare providers diagnose Alzheimer’s disease.

Click here to read the article: www.pharmexec.com/view/fight-alzheimer-research-funding

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic environment.

07/30/2025

Hear Dr. Joel Braunstein, CEO of C2N, speak at the 2025 Alzheimer's Association International Conference (AAIC), going on now in Toronto, Canada. All sessions are held at the Metro Toronto Convention Centre.

He’ll speak at the C2N Product Theater Presentation

12:25 – 13:05
The Power of Precision Diagnostics to Address Clinical Dilemmas Across the AD Continuum
Exhibit Hall – Stage #2

Additional C2N-related session:

14:24 – 14:36
Biomarker development for the tau therapeutic landscape
Location: 718

We encourage you to click this link to schedule a meeting with our team to talk with us about these important new assays to support your latest clinical research studies: https://app.smartsheet.com/b/form/0197128f15c37a018b863cd815eb17d3

07/29/2025

Today, join us for this C2N-related presentation at the 2025 Alzheimer's Association International Conference (AAIC), going on now in Toronto, Canada. All sessions are held at the Metro Toronto Convention Centre.

14:28 – 14:35
Variations in Plasma p-tau217 by Sociodemographic Factors Across World Regions in a Preclinical AD Clinical Trials Program: the AHEAD 3-45 Study

Location: 701

07/29/2025

The 2025 Alzheimer's Association International Conference (AAIC) is going on now in Toronto, Canada.

Don’t forget to visit our C2N booth at 1328.

This year’s AAIC will feature C2N test data in 9 sessions and 23 posters. All sessions are held at the Metro Toronto Convention Centre. Full details at https://c2n.com/newsletters/aaic-2025

Today, join us to hear from Dr. Philip Verghese, SVP of Research and Development and Lab Operations, C2N, from 14:21 – 14:38. He’ll discuss: Cerebrospinal fluid eMTBR-tau243 tau correlates with [18F] GTP1 tau PET and the two biomarkers show similar correlations with clinical measures.

Room 701

07/28/2025

C2N Diagnostics, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, Canada, “A Global Forum to Advance Dementia Science.”

Here are today's C2N-related presentations; all of them are occurring at the Metro Toronto Convention Centre.

14:50 – 15:00
Biological staging of Alzheimer’s disease with the novel plasma eMTBR-tau243 and %p-tau217*
Location: 2-27-FRS-A

16:15 – 16:27
Predicting onset of Alzheimer disease symptoms with a plasma %p-tau217 clock
Location: 105

16:27 – 16:39
Clinical performance of blood biomarkers across settings and countries
Location: Hall F

16:27 – 16:39
Trajectories of CSF and plasma MTBR-tau 243 and phosphorylated-tau species across the Alzheimer’s disease continuum*
Location: 105

16:39 – 16:51
Determining eligibility for anti-amyloid treatments using blood biomarkers
Location: Hall F

*Work done at the Dr. Bateman Lab, Washington University, St. Louis, MO

Also join us for: Spotlight Talk on Blood Biomarkers

16:39 – 16:51
Determining eligibility for anti-amyloid treatments using blood biomarkers
Dr. Suzanne Schindler, Washington University St. Louis, MO

Please also visit our C2N booth #1328.

More details at https://c2n.com/newsletters/aaic-2025

07/28/2025

C2N Diagnostics, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, Canada, “A Global Forum to Advance Dementia Science.”

Here are today's C2N-related presentations; all of them are occurring at the Metro Toronto Convention Centre.

14:50 – 15:00
Biological staging of Alzheimer’s disease with the novel plasma eMTBR-tau243 and %p-tau217*
Location: 2-27-FRS-A

16:15 – 16:27
Predicting onset of Alzheimer disease symptoms with a plasma %p-tau217 clock
Location: 105

16:27 – 16:39
Clinical performance of blood biomarkers across settings and countries
Location: Hall F

16:27 – 16:39
Trajectories of CSF and plasma MTBR-tau 243 and phosphorylated-tau species across the Alzheimer’s disease continuum*
Location: 105

16:39 – 16:51
Determining eligibility for anti-amyloid treatments using blood biomarkers
Location: Hall F

*Work done at the Dr. Bateman Lab, Washington University, St. Louis, MO

Also join us for: Spotlight Talk on Blood Biomarkers

16:39 – 16:51
Determining eligibility for anti-amyloid treatments using blood biomarkers
Dr. Suzanne Schindler, Washington University St. Louis, MO

Please also visit our C2N booth #1328.

More details at https://c2n.com/newsletters/aaic-2025

07/27/2025

Check out the full schedule of C2N Diagnostics at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, Canada from July 26 – 31. https://c2n.com/newsletters/aaic-2025

We also look forward to talking with attendees at our C2N booth (1328).

This year’s AAIC will feature C2N test data in 10 sessions and 23 posters. All sessions are held at the Metro Toronto Convention Centre.

Today’s presentations:

10:15 – 10:30
Blood-Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer’s Disease in the United States
Room 718

17:00 – 17:10
Clinical usefulness of plasma p-tau217 and eMTBR-tau243 combination for diagnosis and patient stratification*
Location: 701
*Work done at the Dr. Bateman Lab, Washington University, St. Louis

We encourage you to click this link to schedule a meeting with our team to talk with us about these important new assays to support your latest clinical research studies: https://app.smartsheet.com/b/form/0197128f15c37a018b863cd815eb17d3

07/27/2025

C2N Diagnostics is excited to attend the Association for Diagnostics & Laboratory Medicine (ADLM) 2025 conference. The theme this year is “Bring the wonder to global laboratory medicine.”

C2N will be at booth -2 (in the Disruptive Technologies area of the exposition hall).

Our experts are eager to meet with you and to share how C2N is developing and commercializing novel diagnostics for Alzheimer’s disease and related forms of neurodegeneration to improve treatment decisions and patients’ lives.

See you in Chicago from July 27-31!

https://meeting.myadlm.org/?_gl=1*kngnsy*_gcl_au*MjIzOTU5MTY3LjE3NTM0NTk1NjM.*_ga*NDg4NzE5NjU5LjE3NTM0NTk1NjI.*_ga_HL3NBSNV7N*czE3NTM0NTk1NjEkbzEkZzEkdDE3NTM0NTk1NzEkajUwJGwwJGgw*_ga_4YF7KENB69*czE3NTM0NTk1NjEkbzEkZzEkdDE3NTM0NTk1NzEkajUwJGwwJGg5OTI3MjQyMDI

07/27/2025

Stop by C2N’s AAIC poster on view today in the Exhibit Hall of the Metro Toronto Conference Center, Poster # SUN799. Dr. Joel Braunstein, CEO of C2N, will be available to discuss “The Economic Utility of an Alzheimer’s Disease Blood Biomarker Test in the Evaluation of Cognitively Impaired Patients.”

Highlights of this study include:

The use of the PrecivityAD2™ blood test to help rule in and rule out amyloid presence prior to CSF or amyloid PET assessment provided:

• In a 1M population covered plan, a cost saving of $21,683,977 and $723/case identified at 40% pe*******on
• Savings could exceed $7B in US-based modeling

Such a high-performance blood test for evaluating AD may provide cost saving, prevent unnecessary testing, and reduce the burden on patients AND the healthcare system!